Use of Continuous Glucose Monitors in Publicly Insured Youth With Type 2 Diabetes: A 12-month Pilot and Feasibility Study.

IF 3.7 Q2 ENDOCRINOLOGY & METABOLISM

Journal of Diabetes Science and Technology Pub Date : 2025-09-20 DOI:10.1177/19322968251368366

Sejal Shah, Molly L Tanenbaum, Alondra Loyola, Nathan Grant L Sala, Himani Darji, Sarah Hanes, Franziska K Bishop, Korey K Hood, David M Maahs

{"title":"Use of Continuous Glucose Monitors in Publicly Insured Youth With Type 2 Diabetes: A 12-month Pilot and Feasibility Study.","authors":"Sejal Shah, Molly L Tanenbaum, Alondra Loyola, Nathan Grant L Sala, Himani Darji, Sarah Hanes, Franziska K Bishop, Korey K Hood, David M Maahs","doi":"10.1177/19322968251368366","DOIUrl":null,"url":null,"abstract":"Background: Type 2 diabetes (T2D) disproportionately affects youth with public insurance of minority and lower socioeconomic status backgrounds. We aimed to determine feasibility of CGM use in this understudied population.Methods: We enrolled youth <20 years old with T2D, provided or prescribed intermittent scanned CGM, and followed established clinic workflows with six data collection visits over 12-months. CGM use was measured by % wear time per two-week period (>75% wear-time as goal) from downloaded report prior to clinic visit. Exploratory outcomes included: 14-day CGM wear time in range (TIR: % time spent between 70 and 180 mg/dl), HbA1c, and patient-reported outcomes (PROs) collected from youth and parents.Results: We enrolled 30 youth (age 15.1 years [SD 2.48]; HbA1c 10.2%, range: 6.5%-15.5%), 46.7% female, 90% Hispanic. At baseline, 37% previously used CGM and 53% lacked glucometer data. CGM use was 50% at three months and 23% at 12 months. CGM wear time decreased by 6.4 days per two weeks by 12 months. Mean HbA1c was 9.8% at 12 months and median TIR decreased from 71% to 42%. Parents and youth had moderate-to-positive attitudes about diabetes technology. Youth endorsed fair levels of global health; and youth and parents endorsed fair general and diabetes-related health-related quality of life.Conclusions: Strategies for sustained CGM use in youth with T2D may differ from adults with T2D or youth with type 1 diabetes. Additional studies are needed to evaluate facilitators and barriers of sustained CGM use to optimize CGM use in youth with T2D.Clinicaltrials: gov registration:NCT05074667.","PeriodicalId":15475,"journal":{"name":"Journal of Diabetes Science and Technology","volume":" ","pages":"19322968251368366"},"PeriodicalIF":3.7000,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12450209/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Diabetes Science and Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/19322968251368366","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Type 2 diabetes (T2D) disproportionately affects youth with public insurance of minority and lower socioeconomic status backgrounds. We aimed to determine feasibility of CGM use in this understudied population.

Methods: We enrolled youth <20 years old with T2D, provided or prescribed intermittent scanned CGM, and followed established clinic workflows with six data collection visits over 12-months. CGM use was measured by % wear time per two-week period (>75% wear-time as goal) from downloaded report prior to clinic visit. Exploratory outcomes included: 14-day CGM wear time in range (TIR: % time spent between 70 and 180 mg/dl), HbA1c, and patient-reported outcomes (PROs) collected from youth and parents.

Results: We enrolled 30 youth (age 15.1 years [SD 2.48]; HbA1c 10.2%, range: 6.5%-15.5%), 46.7% female, 90% Hispanic. At baseline, 37% previously used CGM and 53% lacked glucometer data. CGM use was 50% at three months and 23% at 12 months. CGM wear time decreased by 6.4 days per two weeks by 12 months. Mean HbA1c was 9.8% at 12 months and median TIR decreased from 71% to 42%. Parents and youth had moderate-to-positive attitudes about diabetes technology. Youth endorsed fair levels of global health; and youth and parents endorsed fair general and diabetes-related health-related quality of life.

Conclusions: Strategies for sustained CGM use in youth with T2D may differ from adults with T2D or youth with type 1 diabetes. Additional studies are needed to evaluate facilitators and barriers of sustained CGM use to optimize CGM use in youth with T2D.

Clinicaltrials: gov registration:NCT05074667.

查看原文本刊更多论文

连续血糖监测仪在公共保险青少年2型糖尿病患者中的应用：为期12个月的试点和可行性研究

背景：2型糖尿病（T2D）不成比例地影响少数民族和低社会经济地位背景的公共保险青年。我们的目的是确定在这一未充分研究的人群中使用CGM的可行性。方法：我们从门诊就诊前下载的报告中招募了75%的青少年（以穿戴时间为目标）。探索性结果包括：14天的CGM磨损时间范围（TIR：在70和180 mg/dl之间花费的时间百分比），HbA1c和从青少年和父母那里收集的患者报告结果（PROs）。结果：我们纳入了30名青年（年龄15.1岁[SD 2.48]; HbA1c 10.2%，范围：6.5%-15.5%），46.7%为女性，90%为西班牙裔。在基线时，37%以前使用过CGM， 53%缺乏血糖仪数据。3个月时CGM使用率为50%，12个月时为23%。12个月后，CGM的磨损时间每两周减少6.4天。12个月时平均HbA1c为9.8%，中位TIR从71%降至42%。家长和青少年对糖尿病技术的态度是中等到积极的。青年赞同公平的全球卫生水平；青少年和家长们赞同一般和与糖尿病相关的健康相关的生活质量。结论：青少年T2D患者持续使用CGM的策略可能与成人T2D患者或青少年1型糖尿病患者不同。需要进一步的研究来评估持续使用CGM的促进因素和障碍，以优化青年T2D患者的CGM使用。临床试验：政府注册：NCT05074667。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Diabetes Science and Technology Medicine-Internal Medicine

CiteScore

7.50

自引率

12.00%

发文量

148

期刊介绍： The Journal of Diabetes Science and Technology (JDST) is a bi-monthly, peer-reviewed scientific journal published by the Diabetes Technology Society. JDST covers scientific and clinical aspects of diabetes technology including glucose monitoring, insulin and metabolic peptide delivery, the artificial pancreas, digital health, precision medicine, social media, cybersecurity, software for modeling, physiologic monitoring, technology for managing obesity, and diagnostic tests of glycation. The journal also covers the development and use of mobile applications and wireless communication, as well as bioengineered tools such as MEMS, new biomaterials, and nanotechnology to develop new sensors. Articles in JDST cover both basic research and clinical applications of technologies being developed to help people with diabetes.